CytomX Therapeutics

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
Company Growth (employees)
South San Francisco, US
Size (employees)
78 (est)
CytomX Therapeutics was founded in 2008 and is headquartered in South San Francisco, US

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
100 343 Oyster Point Blvd

CytomX Therapeutics Data and Metrics

CytomX Therapeutics Financial Metrics

CytomX Therapeutics's revenue was reported to be $11.2 m in Q1, 2017

Revenue (Q1, 2017)

11.2 m

Net income (Q1, 2017)

(8.3 m)

EBIT (Q1, 2017)

(8.6 m)

Market capitalization (22-Aug-2017)

542.9 m

Cash (31-Dec-2016)

104.6 m
CytomX Therapeutics's current market capitalization is $542.9 m.
USDFY, 2015FY, 2016


7.7 m15 m

Revenue growth, %



(33.2 m)(59.6 m)

EBIT margin, %


Pre tax profit

(35.4 m)(58.9 m)

Net Income

(35.4 m)(58.9 m)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


1.9 m1.8 m2.5 m2.8 m11.2 m

R&D expense

9.2 m13.4 m12.7 m13.3 m14.6 m

General and administrative expense

4.1 m5 m4.6 m5 m5.7 m

Operating expense total

13.2 m18.4 m17.4 m18.4 m20.3 m


(11.3 m)(16.2 m)(14.3 m)(14.9 m)(8.6 m)

EBIT margin, %


Interest expense

718 k353 k465 k482 k206 k

Interest income

407 k490 k660 k692 k442 k

Pre tax profit

(11.9 m)(16 m)(14.2 m)(14.7 m)

Income tax expense

3 k3 k3 k1 k1 k

Net Income

(11.9 m)(16 m)(14.2 m)(14.7 m)(8.3 m)
USDFY, 2015FY, 2016


59.8 m104.6 m

Accounts Receivable

744 k2.2 m


2.3 m3.9 m

Current Assets

189.8 m188.1 m


3.5 m4.4 m


949 k949 k

Total Assets

197.2 m199.1 m

Accounts Payable

4.7 m6.6 m

Current Liabilities

15.7 m35.8 m

Total Liabilities

120.6 m

Additional Paid-in Capital

243.7 m254.9 m

Retained Earnings

(117.5 m)(176.4 m)

Total Equity

126.1 m78.5 m

Financial Leverage

1.6 x2.5 x
USDFY, 2015FY, 2016

Net Income

(35.4 m)(58.9 m)

Depreciation and Amortization

1.2 m1.7 m

Accounts Receivable

1.1 m(1.8 m)

Accounts Payable

2.9 m1.8 m

Cash From Operating Activities

(27.4 m)(2 m)

Purchases of PP&E

(1.6 m)(2.2 m)

Cash From Investing Activities

(130.6 m)45.9 m

Cash From Financing Activities

153.4 m996 k
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(11.9 m)(16 m)(14.2 m)(14.7 m)(8.3 m)

Accounts Receivable

406 k316 k285 k240 k213 k

Accounts Payable

2.7 m5 m1.4 m517 k3.7 m
USDY, 2017


143.3 k

CytomX Therapeutics Operating Metrics

FY, 2016

Phase I Trials


Phase Preclinical


Patents (US)


Patents (foreign)


Patents Pending


CytomX Therapeutics Market Value History

Traffic Overview of CytomX Therapeutics

CytomX Therapeutics Online and Social Media Presence

CytomX Therapeutics Company Life and Culture

You may also be interested in